
NOV Valuation
Nov Inc
NOV Relative Valuation
NOV's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NOV is overvalued; if below, it's undervalued.
Historical Valuation
Nov Inc (NOV) is now in the Fair zone, suggesting that its current forward PS ratio of 15.40 is considered Fairly compared with the five-year average of 3.92. The fair price of Nov Inc (NOV) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price:15.40
Fair
14.81
PE
1Y
3Y
5Y
Trailing
Forward
7.16
EV/EBITDA
Nov Inc. (NOV) has a current EV/EBITDA of 7.16. The 5-year average EV/EBITDA is 11.50. The thresholds are as follows: Strongly Undervalued below -1.37, Undervalued between -1.37 and 5.06, Fairly Valued between 17.94 and 5.06, Overvalued between 17.94 and 24.37, and Strongly Overvalued above 24.37. The current Forward EV/EBITDA of 7.16 falls within the Historic Trend Line -Fairly Valued range.
11.08
EV/EBIT
Nov Inc. (NOV) has a current EV/EBIT of 11.08. The 5-year average EV/EBIT is -33.71. The thresholds are as follows: Strongly Undervalued below -451.54, Undervalued between -451.54 and -242.62, Fairly Valued between 175.21 and -242.62, Overvalued between 175.21 and 384.12, and Strongly Overvalued above 384.12. The current Forward EV/EBIT of 11.08 falls within the Historic Trend Line -Fairly Valued range.
15.40
PS
Nov Inc. (NOV) has a current PS of 15.40. The 5-year average PS is 0.94. The thresholds are as follows: Strongly Undervalued below -1.37, Undervalued between -1.37 and -0.21, Fairly Valued between 2.09 and -0.21, Overvalued between 2.09 and 3.24, and Strongly Overvalued above 3.24. The current Forward PS of 15.40 falls within the Strongly Overvalued range.
6.78
P/OCF
Nov Inc. (NOV) has a current P/OCF of 6.78. The 5-year average P/OCF is 13.75. The thresholds are as follows: Strongly Undervalued below -38.59, Undervalued between -38.59 and -12.42, Fairly Valued between 39.92 and -12.42, Overvalued between 39.92 and 66.09, and Strongly Overvalued above 66.09. The current Forward P/OCF of 6.78 falls within the Historic Trend Line -Fairly Valued range.
11.28
P/FCF
Nov Inc. (NOV) has a current P/FCF of 11.28. The 5-year average P/FCF is -53.19. The thresholds are as follows: Strongly Undervalued below -674.53, Undervalued between -674.53 and -363.86, Fairly Valued between 257.48 and -363.86, Overvalued between 257.48 and 568.14, and Strongly Overvalued above 568.14. The current Forward P/FCF of 11.28 falls within the Historic Trend Line -Fairly Valued range.
Nov Inc (NOV) has a current Price-to-Book (P/B) ratio of 0.87. Compared to its 3-year average P/B ratio of 1.16 , the current P/B ratio is approximately -24.36% higher. Relative to its 5-year average P/B ratio of 1.19, the current P/B ratio is about -26.22% higher. Nov Inc (NOV) has a Forward Free Cash Flow (FCF) yield of approximately 0.16%. Compared to its 3-year average FCF yield of 4.52%, the current FCF yield is approximately -96.55% lower. Relative to its 5-year average FCF yield of 4.81% , the current FCF yield is about -96.75% lower.
0.87
P/B
Median3y
1.16
Median5y
1.19
15.61
FCF Yield
Median3y
4.52
Median5y
4.81
Competitors Valuation Multiple
The average P/S ratio for NOV's competitors is 34.51, providing a benchmark for relative valuation. Nov Inc Corp (NOV) exhibits a P/S ratio of 15.40, which is -55.37% above the industry average. Given its robust revenue growth of -0.68%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Performance Decomposition
1Y
3Y
5Y
Market capitalization of NOV decreased by 3.41% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 9.47 to 15.46.
The secondary factor is the Revenue Growth, contributed -0.68%to the performance.
Overall, the performance of NOV in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch

LEGN
Legend Biotech Corp
31.800
USD
-1.76%

ASTS
AST SpaceMobile Inc
69.190
USD
+5.99%

MMSI
Merit Medical Systems Inc
87.550
USD
+1.20%

COLB
Columbia Banking System Inc
26.930
USD
+1.93%

HOMB
Home BancShares Inc
27.480
USD
+1.44%

SRAD
Sportradar Group AG
22.970
USD
+0.48%

MAT
Mattel Inc
18.730
USD
+0.32%

HMY
Harmony Gold Mining Company Ltd
16.420
USD
+3.73%

ETSY
ETSY Inc
59.090
USD
+4.03%
FAQ
Is Nov Inc (NOV) currently overvalued or undervalued?
Nov Inc (NOV) is now in the Fair zone, suggesting that its current forward PS ratio of 15.40 is considered Fairly compared with the five-year average of 3.92. The fair price of Nov Inc (NOV) is between to according to relative valuation methord.







